Since these cell biological properties are hallmarks of diseases of the chorioretinal interface, it is tempting to speculate that the inhibition of galectin-3 in RPE cells could be a potential option for the treatment of these diseases, including proliferative vitreoretinopathy, diabetic retinopathy, or wet age-related macular degeneration. The gene discussed is LGALS3; the disease is diabetic retinopathy.